The study included SAD and MAD components to assess KIT2014’s safety and tolerability, as well as monitor plasma ...

The biotechnology sector is in focus following reports that AbbVie (ABBV) is nearing an acquisition of Apogee Therapeutics ...

Biotech stocks are outperforming the broader market as growth investors return and M&A activity supports valuations across ...

SEC-registered, FINRA-member platform expands capital access for life science innovators SAN DIEGO, CA, UNITED STATES, ...

AbbVie Inc. is dipping into its coffers to finance a $10.9 billion acquisition of a Boston-area biotech with Bay Area ...

Intellia's CRISPR pipeline and Omeros's newly approved therapy each bring unique risk and reward profiles, see how their ...

The pharmaceutical industry is known for big risks and big rewards among investors; those willing to take on the risk may ...

Driven by looming patent cliffs, newly buoyant public markets, and Big Pharma's race to beef up their pipelines, dealmaking in 2026 is off to a strong start.

They have at least one thing in common: An exciting pipeline.

Vedana Therapeutics emerged from stealth with a $46M Series A.

As AI transforms biology, longevity startups are attracting investors, advancing toward clinical milestones, and reshaping ...

Biopharma dealmaking is driven by pressure to top up drug pipelines ahead of major patent expirations later this decade.